Selpercatinib (Retevmo) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
  • InChIKey: XIIOFHFUYBLOLW-UHFFFAOYSA-N
  • Mol. Mass: 525.61
  • ALogP: 3.28
  • ChEMBL Molecule:
    selpercatinib  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$85.2250 - $163.9028
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

loxo-292

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (3)


 

Carcinoma, Medullary

Carcinoma, Non-Small-Cell Lung (approved 2020)

Thyroid Neoplasms (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Carcinoma, Medullary ()

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colonic Neoplasms (Phase 1)

Ependymoma (Phase 2)

Fibrosarcoma (Phase 1/Phase 2)

Glioma (Phase 2)

Healthy Volunteers (Phase 1/Phase 2)

Hepatoblastoma (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Leukemia, Hairy Cell (Phase 2)

Liver Diseases (Phase 1/Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Medulloblastoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neuroblastoma (Phase 2)

Neuroectodermal Tumors (Phase 2)

Osteosarcoma (Phase 2)

Renal Insufficiency (Phase 1)

Rhabdoid Tumor (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Thyroid Cancer, Papillary (Phase 2)

Thyroid Neoplasms (Phase 3)

Wilms Tumor (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue